Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224786 | 0.72 | — | — | |
| SCHEMBL9107638 | 0.63 | NR1H2 (0.38) | — | |
| SCHEMBL2465460 | 0.57 | — | — | |
| SCHEMBL2857054 | 0.54 | — | — | |
| SCHEMBL27481762 | 0.52 | LMNA (0.30) | — | |
| Urea SCHEMBL5080024 | 0.51 | — | — | |
| SCHEMBL254299 | 0.48 | — | — | |
| Methylsulfanylmethane SCHEMBL28433514 | 0.48 | — | — | |
| Urea SCHEMBL27860084 | 0.48 | — | — | |
| Urea SCHEMBL27699496 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1339702-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2001068619-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-1998005651-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYL QUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | PDPK1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.